Trials
3 active
14 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary IgA Nephropathy (2 trials), Paroxysmal Nocturnal Hemoglobinuria
- Main trialPhase 3
- “This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.”In the company’s words, NCT07014826 on ClinicalTrials.gov
Other drugs for Primary IgA Nephropathy
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- IptacopanNovartis · Phase 3
- AtaciceptVera Therapeutics, Inc. · Phase 3
Coming up3
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07014826
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Oct 2027 | A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | |
| Phase 2Active, not recruiting | Dec 2027 | Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 2Recruiting | Jul 2029 | A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy | |
| Phase 3Completed | 31 Jul 2025 | A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy | |
| Phase 3Completed | 6 Jan 2026 | Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment | |
| Phase 2Completed | 25 Mar 2024 | Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 2Completed | 17 Oct 2025 | A Trial of HRS-5965 Tablets in Primary IgA Nephropathy | |
| Phase 1Completed | 3 Nov 2023 | Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency | |
| Phase 1Completed | 6 Aug 2024 | Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects | |
| Phase 1Completed | 8 Oct 2024 | A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers | |
| Phase 1Completed | 7 Apr 2025 | A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects | |
| Phase 1Completed | 22 Jul 2025 | A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects | |
| Phase 1Completed | 17 Aug 2025 | Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects | |
| Phase 1Completed | 16 Jan 2026 | Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026